Is the Incidence of Differentiated Thyroid Cancer Increased in Patients with Thyrotropin-Secreting Adenomas? Report of Three Cases from a Large Consecutive Series

Perticone, F.; Pigliaru, Francesco; Mariotti, Stefano; Deiana, Luca; Furlani, Lino; Mortini, Pietro; Losa, Marco

doi:10.1089/thy.2014.0222

Cited by 28 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differentiated thyroid cancer (DTC) is a popular subtype of thyroid cancer and it accounts for over 90% of all thyroid carcinomas, which includes several other subtypes such as follicular thyroid cancer (FTC) and papillary thyroid carcinoma (PTC) [4][5][6][7]. The incidences of FTC and PTC are two to four times higher in females than that in males, as a consequence, thyroid cancer becomes the eighth most common cancer occurred in females [6,8]. So far, ionizing radiation (IR) is the only established risk factor for thyroid cancer [6,8].…”

Section: Introductionmentioning

confidence: 99%

“…The incidences of FTC and PTC are two to four times higher in females than that in males, as a consequence, thyroid cancer becomes the eighth most common cancer occurred in females [6,8]. So far, ionizing radiation (IR) is the only established risk factor for thyroid cancer [6,8]. However, ionizing radiation does not always trigger thyroid cancer because both environmental agents and genetic factors could exert important roles in thyroid carcinogenesis [3,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association Studies Between XRCC1, XRCC2, XRCC3 Polymorphisms and Differentiated Thyroid Carcinoma

Yan¹,

Li²,

Li³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: DNA HRR pathway and BER pathway play vital roles in differentiated thyroid cancer (DTC) development, thus we supposed that polymorphisms of XRCC1, XRCC2, XRCC3 DNA repair genes are associated with thyroid cancer risk and progression. Methods: We searched the NCBI database for relevant literatures to determine eight SNPs to be included in our study (XRCC1: rs25487, rs25489, rs1799782; XRCC2: rs3218536; XRCC3: rs1799794, rs56377012, rs1799796, rs861539). Results: SNP of rs25487 was linked with a 53% decrease in DTC risk (OR: 0.47; 95%CI: 0.268-0.82; P = 0.01). For SNP of rs1799782, the homozygous TT genotype indicated a statistically significant 2-fold increased risk of DTC (OR: 2.09; 95%CI: 1.27-3.43; P < 0.001) after multivariate adjustment. For SNP of rs861539, the homozygous TT genotype suggested statistically significant 3-fold increased risk of DTC (OR: 3.02; 95%CI: 1.68-5.42; P < 0.001). No significant association between the other five SNPs and DTC risk. Besides that, female was linked with 47% increase in DTC risk (OR: 1.47; 95%CI: 1.062-2.04; P = 0.02) after multivariate adjustment. Similar results for most of the SNPs were obtained from subgroup analysis by different histological types of DTC. Haplotype analysis revealed that AGC and GGT haplotypes of XRCC1 polymorphisms were associated with DTC. Moreover, results from gene-gene interaction showed that XRCC1-rs25487, XRCC1- rs1799782 and XRCC3- rs861539 variants jointly contributed to a specifically increased risk of DTC, with the combination variant of rs1799782-CT heterozygote and rs861539-TT homozygote exhibiting a higher 3.66-fold risk of DTC (OR: 3.66; 95% CI: 1.476-9.091, P = 0.005). Conclusion: Polymorphisms of XRCC1 (rs25487, rs1799782) and XRCC3 (rs861539), may play a critical role in DTC development and progression. Furthermore, XRCC1 variant can interact with XRCC3 variant to significantly increase DTC susceptibility. Identifying these genetic risk markers could provide evidence for exploring the insight pathogenesis and develop novel therapeutic strategies for DTC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association Studies Between XRCC1, XRCC2, XRCC3 Polymorphisms and Differentiated Thyroid Carcinoma

Yan¹,

Li²,

Li³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…The exclusion criteria were (1) treatment with drugs potentially causing osteoporosis and fractures [22]; (2) treatment with bone-active drugs, except for calcium and vitamin D at the time of VF evaluation; and (3) history of thyroidectomy and/or neck radiotherapy [23]. …”

Section: Methodsmentioning

confidence: 99%

“…The criteria used for the selection were (1) diagnosis of NFPA, (2) comparable age and sex to the cases with a 2:1 ratio, and (3) availability of thoracic X-rays. Exclusion criteria were (1) history of hyperthyroidism; (2) treatment with drugs potentially causing osteoporosis and fractures [22]; (3) treatment with bone-active drugs, except for calcium and vitamin D at the time of VF evaluation; and (4) history of thyroidectomy and/or neck radiotherapy [23]. …”

Section: Methodsmentioning

confidence: 99%

High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma

Frara

Losa

Doga

et al. 2018

Journal of the Endocrine Society

Self Cite

View full text Add to dashboard Cite

BackgroundBone loss and high risk of fractures have been reported in patients with primary hyperthyroidism, whereas data on skeletal health in TSH-secreting adenoma (TSH-oma) are scant, and the risk of fractures in this specific clinical context has not been investigated so far. In this cross-sectional study, we aimed at evaluating for the first time, to our knowledge, the prevalence and determinants of radiological vertebral fractures (VFs) in patients with TSH-oma.MethodsTwenty-two patients (10 males, 12 females; median age 47 years) with TSH-oma and 44 patients (20 males, 24 females; median age 49 years) with nonfunctioning pituitary adenoma (NFPA) were retrospectively evaluated for thoracic VFs using a morphometric approach on lateral chest X-ray routinely performed in the presurgical diagnostic workup.ResultsThe prevalence of VFs was significantly higher in TSH-oma vs NFPA (59.1% vs 22.7%; P = 0.003), the difference being still significant (odds ratio, 10.5; P = 0.005) after correction for the size of pituitary adenomas and biochemical parameters. In TSH-oma, the prevalence of VFs was significantly associated with older age (P = 0.007) and higher serum free T4 values (P = 0.02). In 20 patients, data on presurgical medical therapies of TSH-oma were available. All patients not treated with somatostatin receptor ligands were fractured compared with 25% of those who were treated with these drugs (P = 0.001). No significant (P = 0.25) association between VFs and treatment with methimazole was found.ConclusionsThis study provides the first evidence, to our knowledge, that patients with TSH-oma may develop VFs in close relationship with severity of hyperthyroidism.

show abstract

“…Наличие зоба, как правило, выявляется даже у пациентов с предшествующей частичной тиреоидэктомией из-за роста остаточной ткани щитовидной железы. Дифференцированный рак щитовидной железы описан у нескольких больных с ТТГ-АГ [23][24][25][26]. У пациентов с узловым зобом необходимо проведение мониторинга узлов щитовидной железы и проведение тонкоигольной аспирационной биопсии.…”

Section: Discussionunclassified

Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas

et al. 2016

View full text Add to dashboard Cite

show abstract

Is the Incidence of Differentiated Thyroid Cancer Increased in Patients with Thyrotropin-Secreting Adenomas? Report of Three Cases from a Large Consecutive Series

Cited by 28 publications

References 27 publications

Association Studies Between XRCC1, XRCC2, XRCC3 Polymorphisms and Differentiated Thyroid Carcinoma

Association Studies Between XRCC1, XRCC2, XRCC3 Polymorphisms and Differentiated Thyroid Carcinoma

High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma

Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas

Contact Info

Product

Resources

About